ConvaTec Group PLC Director/PDMR Shareholding (5861Y)
07 December 2017 - 12:54AM
UK Regulatory
TIDMCTEC
RNS Number : 5861Y
ConvaTec Group PLC
06 December 2017
6 December 2017
ConvaTec Group Plc
("ConvaTec" or "the Company")
Director/PDMR Shareholding
The Company has been notified of the following transaction by a
Person Discharging Managerial Responsibility ("PDMR") in ordinary
shares of 10 pence each in the share capital of the Company
("Shares").
On 6 December 2017, Dr Ros Rivaz, a Non-Executive Director and a
PDMR, purchased 4,821 Shares at GBP2.06 per share. Dr Rivaz'
resulting shareholding is 9,729 Shares.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial
responsibilities/person closely associated
---- --------------------------------------------------------------------------------------------------
a) Name Dr Rosalind Rivaz
---- -------------------------------- ----------------------------------------------------------------
2 Reason for the notification
---- --------------------------------------------------------------------------------------------------
a) Position/Status Non-Executive Director
---- -------------------------------- ----------------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- -------------------------------- ----------------------------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- --------------------------------------------------------------------------------------------------
a) Name ConvaTec Group Plc
---- -------------------------------- ----------------------------------------------------------------
b) LEI 213800LS272L4FIDOH92
---- -------------------------------- ----------------------------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
---- --------------------------------------------------------------------------------------------------
a) Description of the Ordinary shares of 10p each in ConvaTec Group Plc ("Shares")
financial instrument, GB00BD3VFW73
type of instrument
Identification code
---- -------------------------------- ----------------------------------------------------------------
b) Nature of the transaction Purchase of Shares
---- -------------------------------- ----------------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP2.0615 4,821
---- -------------------------------- --------------------------------- -----------------------------
d) Aggregated information
- Aggregated volume 4,821
- Price GBP9,938.49
---- -------------------------------- ----------------------------------------------------------------
e) Date of the transaction 6 December 2017
---- -------------------------------- ----------------------------------------------------------------
f) Place of the transaction London Stock Exchange, Main Market (XLON)
---- -------------------------------- ----------------------------------------------------------------
Enquiries
Media
Bobby Leach, VP Group Corporate Affairs, ConvaTec +44 (0)7770 842 226
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, ConvaTec +44 (0)7500 141
435
Kirsty Law, Director Investor Relations, ConvaTec +44 (0)7470 909 582
investorrelations@convatec.com
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions, with
leading market positions in advanced wound care, ostomy care,
continence and critical care, and infusion devices. ConvaTec's
products provide a range of clinical and economic benefits
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care. To learn
more about ConvaTec, please visit www.convatecgroup.com where a
copy of this announcement can also be found.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFEVFLLRIID
(END) Dow Jones Newswires
December 06, 2017 08:54 ET (13:54 GMT)
Convatec (LSE:CTEC)
Historical Stock Chart
From Apr 2024 to May 2024
Convatec (LSE:CTEC)
Historical Stock Chart
From May 2023 to May 2024